FHI 360 participates in the Sexually Transmitted Infections Clinical Trials Group (STI-CTG), a collaboration of institutions that work together to develop and administer a research program (clinical research and trials) that will contribute to human reproductive health and specifically lead to the prevention and control of sexually transmitted infections (STIs). The STI-CTG research agenda encompasses the safety and efficacy of new diagnostics, therapeutics, vaccines and behavioral interventions aimed at preventing and controlling diseases or pathogens such as chlamydial infection, gonorrhea, syphilis, chancroid, human papillomavirus, herpes simplex virus 1 and 2, and HIV as it is associated with other STIs.
FHI 360 serves as the operations center for the STI-CTG, participating in and providing a broad range of support for the group’s leadership and for study development and implementation under the direction of the Division of Microbiology and Infectious Diseases of the U.S. National Institute of Allergy and Infectious Diseases and in partnership with the University of Alabama at Birmingham.
